BUSINESS

• Teijin Gets Japan Rights to Versartis’ Growth Hormone Deficiency Treatment
  August 15, 2016

• JT/Torii License Menlo’s Pruritus Candidate for Japan Market
  August 15, 2016

• Sawai Eyes First-to-File Status for 5 Generics in the US
  August 10, 2016

• Japan PII Now Underway for Otsuka’s DMD Candidate TAS-205
  August 10, 2016

• Otsuka Suffers Big Drops in Pharma Sales, Profit on US Abilify Patent Loss
  August 10, 2016

• Astellas Files Japan NDA for Quetiapine for Bipolar Disorder
  August 10, 2016

• Kissei, JCR Kick Off Japan PIII for Nesp Biosimilar
  August 10, 2016

• Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End
  August 10, 2016

• Ono Rushes to Soothe Investor Nerves over Opdivo PIII Data
  August 10, 2016

• Opdivo Disappoints in 1st-Line Lung Cancer Trial
  August 9, 2016

• Carna Biosciences, Janssen Call Off Licensing Deal for Kinase Inhibitor
  August 8, 2016

• Takeda, Pfizer to Wind Up Sales Deal for Prevenar, BeneFIX
  August 8, 2016

• Meiji Seika Pharma Licenses Therapeutic Candidate Substance for Multiple Sclerosis to Curadim Pharma
  August 8, 2016

• Astellas to Transfer US Manufacturing Unit to Avara
  August 5, 2016

• Sumitomo Dainippon to Nurture Specialized Reps as It Pushes Oncology, Other Biz Focus
  August 5, 2016

• Rohto, Osaka Univ. Tie Up for Stem Cell Research, Aim for Approval of Regenerative Medicine Products
  August 5, 2016

• Zafatek Most Heavily Promoted Drug in GP Market in June: Anterio
  August 4, 2016

• Teijin Jettisons Extended-Release Version of Feburic; Successor Now in PI
  August 3, 2016

• Mitsubishi Tanabe Erases Alzheimer’s Drug from Japan Pipeline
  August 3, 2016

• Adcetris Shows Positive Efficacy Profile in Cutaneous T-Cell Lymphoma
  August 3, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 450
• 451
• 452
• 453
• 454
• 455
• 456
• 457
• 458
• …
• Next ›
• 最終 »